A Randomized, Double-blind, Phase III Study Assessing Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis

Abstract

Ustekinumab is a safe and effective treatment for moderate-to-severe psoriasis. To compare efficacy, safety, pharmacokinetics (PK), and immunogenicity of the proposed ustekinumab biosimilar SB17 with reference ustekinumab (UST) in subjects with moderate to severe plaque psoriasis. In this randomized double-blind study, subjects were randomized to receive 45 mg of SB17 or UST subcutaneously at Week 0, 4, and every 12 weeks. The primary endpoint was the percent change from baseline in Psoriasis Area and Severity Index (PASI) at Week 12 with an equivalence margin of [-15%, 15%]. Other secondary efficacy, safety, PK, and immunogenicity endpoints were measured through Week 28. 249 subjects were randomized to SB17, 254 to UST. Adjusted difference of PASI change from baseline at Week 12 of -0.6% (95% confidence interval [CI; -3.780, 2.579]) was within the equivalence margin. Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI) were also comparable. Overall treatment-emergent adverse events (TEAEs) were comparable (SB17: 48.2%, UST: 48.8%). The overall incidence of anti-drug antibodies (ADAs) up to Week 28 was 13.3% with SB17 and 39.4% with UST. Data were only through Week 28. SB17 was clinically biosimilar to UST up to Week 28.